Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P. Grossi F, et al. Among authors: defferrari c. Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21. Cancer Chemother Pharmacol. 2012. PMID: 22349923 Clinical Trial.
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, Grossi F. Belvedere O, et al. Among authors: defferrari c. Eur J Cancer. 2011 Jul;47(11):1653-9. doi: 10.1016/j.ejca.2011.03.020. Epub 2011 Apr 20. Eur J Cancer. 2011. PMID: 21514147 Clinical Trial.
Maintenance chemotherapy in non-small cell lung cancer.
Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, Grossi F. Rinaldi M, et al. Among authors: defferrari c. Ann Oncol. 2006 Mar;17 Suppl 2:ii67-70. doi: 10.1093/annonc/mdj928. Ann Oncol. 2006. PMID: 16608989 Free article. Review. No abstract available.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D. Passiglia F, et al. Among authors: defferrari c. Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31. Br J Cancer. 2019. PMID: 30377342 Free PMC article.
Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.
Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A. Puntoni M, et al. Among authors: defferrari c. Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4. Cancer Prev Res (Phila). 2016. PMID: 27045034 Clinical Trial.
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG, Scagliarini S, Galli L, Pignata S, Lo Re G, Berruti A, Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C, Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C, Sabbatini R. Vitale MG, et al. Among authors: defferrari c. PLoS One. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. eCollection 2018. PLoS One. 2018. PMID: 29979712 Free PMC article.
17 results